Liver Disease Clinical Trials

Showing 261-280 of 1,498 trials

Digital Pathology and AI for Liver Outcomes in MASLD (DPAILO-2)

NCT06493253

The aim of this multi-center, retrospective epidemiologic study is to confirm the prognostic performance of the Digital Pathology (DP) FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS), derived from standard digital pathology liver biopsy images, in predicting clinical hepatic decompensation events in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Metabolic Dysfunction-associated Steatotic Liver Disease

PharmaNest, Inc1,700 participantsStarted Sep 2025

Richmond, Virginia, United States

COMPLETEDPhase 2

Comparison of Effectiveness of Obeticholic Acid With Vitamin E in Patients of Non-alcoholic Fatty Liver Disease

NCT07104786

This study was conducted on patients presenting to Mayo Hospital, Lahore from 24th August, 2023 till 23rd May, 2024. Ninety patients conforming to the inclusion criteria were selected via simple random sampling technique and divided into two groups. Group A received Obeticholic acid 10mg once a day and Group B received Vitamin E 400mg twice a day. Both treatments were given for 6 months alongwith clear written and informed instructions regarding lifestyle modification. Patients were followed at 3 and 6 months with ultrasound abdomen and serum alanine transferase levels.

Non Alcoholic Fatty Liver Disease

King Edward Medical University90 participantsStarted Aug 2023

Lahore, Punjab Province, Pakistan

Active Not RecruitingPhase 3

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

NCT04951219

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)

Non-Alcoholic Fatty Liver Disease

Madrigal Pharmaceuticals, Inc.1,000 participantsStarted Jul 2021

Birmingham, Alabama, United States • Chandler, Arizona, United States • Chandler, Arizona, United States +68 more locations

Digital Pathology and AI for Liver Outcomes in MASLD (DPAILO-2)

Comparison of Effectiveness of Obeticholic Acid With Vitamin E in Patients of Non-alcoholic Fatty Liver Disease

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Related Searches

Assessment of Tolerability of Specialized Food Products Made Out of Vegetable Protein and Their Influence on Lipid Profile in Patients With Non-alcoholic Fatty Liver Disease

Effect of Adjustable Intragastric Balloon in Obese Non-alcoholic Fatty Liver Disease

Evaluation of a Nutrition Education Guide for Patients With Cirrhosis

Lifestyle Habits and Metabolic Dysfunction-Associated Steatotic Liver Disease in Youth

A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor

Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease

The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis

A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine

Digital Therapeutic Lifestyle Intervention Program for Patients With MASLD

Prognostic Model for MASLD Related Cirrhosis

HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease

Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly

Fibrinogen Concentrates Versus Cryoprecipitate in Liver Transplant Surgery

Effects of Normobaric Hypoxic Training in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load

A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems